162 related articles for article (PubMed ID: 33378953)
1. The oncogenic role of HBXIP.
Xiu M; Zeng X; Shan R; Wen W; Li J; Wan R
Biomed Pharmacother; 2021 Jan; 133():111045. PubMed ID: 33378953
[TBL] [Abstract][Full Text] [Related]
2. The oncoprotein HBXIP promotes human breast cancer growth through down-regulating p53 via miR-18b/MDM2 and pAKT/MDM2 pathways.
Li H; Wang Z; Jiang M; Fang RP; Shi H; Shen Y; Cai XL; Liu Q; Ye K; Fan SJ; Zhang WY; Ye LH
Acta Pharmacol Sin; 2018 Nov; 39(11):1787-1796. PubMed ID: 30181579
[TBL] [Abstract][Full Text] [Related]
3. Oncoprotein HBXIP Modulates Abnormal Lipid Metabolism and Growth of Breast Cancer Cells by Activating the LXRs/SREBP-1c/FAS Signaling Cascade.
Zhao Y; Li H; Zhang Y; Li L; Fang R; Li Y; Liu Q; Zhang W; Qiu L; Liu F; Zhang X; Ye L
Cancer Res; 2016 Aug; 76(16):4696-707. PubMed ID: 26980761
[TBL] [Abstract][Full Text] [Related]
4. Structural characterization of HBXIP: the protein that interacts with the anti-apoptotic protein survivin and the oncogenic viral protein HBx.
Garcia-Saez I; Lacroix FB; Blot D; Gabel F; Skoufias DA
J Mol Biol; 2011 Jan; 405(2):331-40. PubMed ID: 21059355
[TBL] [Abstract][Full Text] [Related]
5. The oncoprotein HBXIP enhances angiogenesis and growth of breast cancer through modulating FGF8 and VEGF.
Liu F; You X; Wang Y; Liu Q; Liu Y; Zhang S; Chen L; Zhang X; Ye L
Carcinogenesis; 2014 May; 35(5):1144-53. PubMed ID: 24464787
[TBL] [Abstract][Full Text] [Related]
6. The regulation of acetylation and stability of HMGA2 via the HBXIP-activated Akt-PCAF pathway in promotion of esophageal squamous cell carcinoma growth.
Wu Y; Wang X; Xu F; Zhang L; Wang T; Fu X; Jin T; Zhang W; Ye L
Nucleic Acids Res; 2020 May; 48(9):4858-4876. PubMed ID: 32313942
[TBL] [Abstract][Full Text] [Related]
7. The oncoprotein HBXIP suppresses gluconeogenesis through modulating PCK1 to enhance the growth of hepatoma cells.
Shi H; Fang R; Li Y; Li L; Zhang W; Wang H; Chen F; Zhang S; Zhang X; Ye L
Cancer Lett; 2016 Nov; 382(2):147-156. PubMed ID: 27609066
[TBL] [Abstract][Full Text] [Related]
8. The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer.
Li H; Liu Q; Wang Z; Fang R; Shen Y; Cai X; Gao Y; Li Y; Zhang X; Ye L
J Biol Chem; 2015 Sep; 290(37):22649-61. PubMed ID: 26229107
[TBL] [Abstract][Full Text] [Related]
9. Research progress on oncoprotein hepatitis B X‑interacting protein (Review).
Cheng L; Guo L; Zou T; Yang Y; Tao R; Liu S
Mol Med Rep; 2024 Jun; 29(6):. PubMed ID: 38577934
[TBL] [Abstract][Full Text] [Related]
10. The oncoprotein hepatitis B X-interacting protein promotes the migration of ovarian cancer cells through the upregulation of S-phase kinase-associated protein 2 by Sp1.
Xu F; Zhu X; Han T; You X; Liu F; Ye L; Zhang X; Wang X; Yao Y
Int J Oncol; 2014 Jul; 45(1):255-63. PubMed ID: 24788380
[TBL] [Abstract][Full Text] [Related]
11. The oncoprotein HBXIP upregulates PDGFB via activating transcription factor Sp1 to promote the proliferation of breast cancer cells.
Zhang Y; Zhao Y; Li L; Shen Y; Cai X; Zhang X; Ye L
Biochem Biophys Res Commun; 2013 May; 434(2):305-10. PubMed ID: 23537647
[TBL] [Abstract][Full Text] [Related]
12. The oncoprotein HBXIP promotes glucose metabolism reprogramming via downregulating SCO2 and PDHA1 in breast cancer.
Liu F; Zhang W; You X; Liu Y; Li Y; Wang Z; Wang Y; Zhang X; Ye L
Oncotarget; 2015 Sep; 6(29):27199-213. PubMed ID: 26309161
[TBL] [Abstract][Full Text] [Related]
13. HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g.
Cai X; Wang X; Cao C; Gao Y; Zhang S; Yang Z; Liu Y; Zhang X; Zhang W; Ye L
Cancer Lett; 2018 Feb; 415():11-19. PubMed ID: 29174803
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic HBXIP enhances ZEB1 through Sp1 to accelerate breast cancer growth.
Jiang Y; Wang D; Ren H; Shi Y; Gao Y
Thorac Cancer; 2018 Dec; 9(12):1664-1670. PubMed ID: 30273966
[TBL] [Abstract][Full Text] [Related]
15. The oncoprotein HBXIP competitively binds KEAP1 to activate NRF2 and enhance breast cancer cell growth and metastasis.
Zhou XL; Zhu CY; Wu ZG; Guo X; Zou W
Oncogene; 2019 May; 38(21):4028-4046. PubMed ID: 30692632
[TBL] [Abstract][Full Text] [Related]
16. Oncoprotein HBXIP induces PKM2 via transcription factor E2F1 to promote cell proliferation in ER-positive breast cancer.
Liu BW; Wang TJ; Li LL; Zhang L; Liu YX; Feng JY; Wu Y; Xu FF; Zhang QS; Bao MZ; Zhang WY; Ye LH
Acta Pharmacol Sin; 2019 Apr; 40(4):530-538. PubMed ID: 29925919
[TBL] [Abstract][Full Text] [Related]
17. HBXIP up-regulates ACSL1 through activating transcriptional factor Sp1 in breast cancer.
Wang Y; Cai X; Zhang S; Cui M; Liu F; Sun B; Zhang W; Zhang X; Ye L
Biochem Biophys Res Commun; 2017 Mar; 484(3):565-571. PubMed ID: 28132807
[TBL] [Abstract][Full Text] [Related]
18. The oncoprotein HBXIP up-regulates SCG3 through modulating E2F1 and miR-509-3p in hepatoma cells.
Wang Y; Cui M; Cai X; Sun B; Liu F; Zhang X; Ye L
Cancer Lett; 2014 Oct; 352(2):169-78. PubMed ID: 24882622
[TBL] [Abstract][Full Text] [Related]
19. Mitochondria: The metabolic switch of cellular oncogenic transformation.
Tan YQ; Zhang X; Zhang S; Zhu T; Garg M; Lobie PE; Pandey V
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188534. PubMed ID: 33794332
[TBL] [Abstract][Full Text] [Related]
20. HBXIP suppression reduces cell proliferation and migration and its overexpression predicts poor prognosis in non-small-cell lung cancer.
Wang Y; Li N; Che S; Jin T; Piao J; Liu S; Lin Z
Tumour Biol; 2017 Jul; 39(7):1010428317709675. PubMed ID: 28718367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
